Company intelligence / Profile preview

OxThera AB

Ownership: Private
Development stage: Phase 3

Overview

OxThera’s lead product, Oxabact®, an oral formulation of highly concentrated lyophilized Oxalobacter formigenes, has received Rare Pediatric Disease Designation from the US FDA for Primary Hyperoxaluria. Clinical data presented includes results from a 24-month study. The company also develops Oxazyme®, a recombinant oxalate decarboxylase enzyme therapy targeting dietary oxalate

Therapeutic areas: Rare DiseasesNephrology
Modalities: Live biotherapeutic products (LBPs), specifically orally administered live bacteria (Oxalobacter formigenes)recombinant enzyme therapy
Industry: Biotech

Drug pipeline

1 asset

Oxabact

Phase 3

Indications: Primary Hyperoxaluria

Beyond the preview

Go deeper on OxThera AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OxThera AB.